Clinical trials and Haemophilia during the COVID-19 pandemic: Madrid's experience

This is the peer reviewed version of the following article: "Clinical trials and Haemophilia during the COVID‐19 pandemic: Madrid's experience". Haemophilia (2020): 16 May, which has been published in final form at https://doi.org/10.1111/hae.14055. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Version

Impact of Covid-19 pandemic on patients with immune thrombocytopaenia

Background and Objectives: The aim of this study was to determine the impact of the COVID-19 pandemic on the lives of patients with immune thrombocytopaenia (ITP) treated at our hospital. Materials and Methods: The study was conducted in the Community of Madrid, which has the highest number of COVID-19 cases in Spain. We included 143 adult patients with ITP (130 with chronic ITP, 8 with persistent ITP, and 5 with newly diagnosed ITP). We conducted a telephone survey to collect the data and created a registry. Materials and Methods: Overall, 24 patients presented symptoms suggestive of COVID-19, which was confirmed by RT-PCR in 8 cases. The cumulative incidence of confirmed SARS-CoV-2 infection was higher in the patients with ITP than in the Madrid population. There were no differences in the disease incidence or clinical course of infection in the patients treated with immunosuppressants. Almost all of the patients reported adherence to the prescribed treatment, although 49.2% of the hospital visits were either cancelled or postponed, 17.2% because of the patients’ fear of coming to the centre. Nearly half of the cohort was considered vulnerable, and 17% had been granted a dependency or disability benefit. Conclusions: COVID-19 had a major impact on the psychosocial, occupational, and quality of care of patients with ITP.This study was supported by FIS-Fondos FEDER PI19/00631 and PI19/00772 and by the Platelet Disorder Support Associatio

The importance of platelet glycoside residues in the haemostasis of patients with immune thrombocytopaenia

Loss of sialic acid from the carbohydrate side chains of platelet glycoproteins can affect platelet clearance, a proposed mechanism involved in the etiopathogenesis of immune thrombocy-topaenia (ITP). We aimed to assess whether changes in platelet glycosylation in patients with ITP affected platelet counts, function, and apoptosis. This observational, prospective, and transversal study included 82 patients with chronic primary ITP and 115 healthy controls. We measured platelet activation markers and assayed platelet glycosylation and caspase activity, analysing samples using flow cytometry. Platelets from patients with ITP with a platelet count <30 × 103/µL presented less sialic acid. Levels of α1,6-fucose (a glycan residue that can directly regulate antibody-dependent cellular cytotoxicity) and α-mannose (which can be recognised by mannose-binding-lectin and acti-vate the complement pathway) were increased in the platelets from these patients. Platelet surface exposure of other glycoside residues due to sialic acid loss inversely correlated with platelet count and the ability to be activated. Moreover, loss of sialic acid induced the ingestion of platelets by human hepatome HepG2 cells. Changes in glycoside composition of glycoproteins on the platelets’ surface impaired their functional capacity and increased their apoptosis. These changes in platelet glycoside residues appeared to be related to ITP severity.This research was funded by FIS-Fondos FEDER PI19/00631, FIS-Fondos FEDER PI19/00772 and Platelet Disorder Support Associatio

Synthesis and Applications of Pd Immobilized Catalysts for C-C Coupling Reactions

Treball de Final de Grau en Química. Codi: QU0943. Curs acadèmic 2015-201

Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic

Key Clinical Message Switching to rIX‐FP prophylaxis at dosing intervals of up to 14 days in a hemophilia B pediatric patient decreased treatment burden by reducing the number of administrations and hospital visits, without affecting efficacy or treatment adherence. This is particularly important in contexts of limited mobility and overloaded healthcare services

Right subclavian artery and its variant

Catedra Anatomia Omului, USMF „Nicolae Testemiţanu”A thorough description of right subclavian artery variant, rarely encountered, starting from the postero-inferior part of the aortic arch at the limit with the descending aorta, and then placed between the spine and esophagus, n. vagus, thoracic lymphatic duct – all these denote its place in the posterior mediastinum – a dangerous position for it, but clinically not manifested. Aberrant right subclavian artery is combined with other variants of the large blood vessels: the truncus bicaroticus, formed by a. carotis communis dextra et sinister and some variants of the branches of the right or left subclavian arteries. Descrierea minuţioasă a variantei a. subclavia dextra, rar întâlnită, care începe de la partea postero-inferioară al arcului aortei la limita cu aorta descendentă, aşezată apoi între coloana vertebrală şi esofag, nervul vag drept, ductul limfatic toracic, denotă localizarea ei în mediastinul posterior, o poziţie periculoasă pentru ea, dar care în majoritatea cazurilor nu se manifestă clinic. Aberanţa arterei subclaviculare drepte se îmbină cu alte variante ale vaselor sangvine mari: ca truncus bicaroticus, format din a. carotis communis dextra et sinistra, cât şi unele variante ale ramurilor a. subclavia dextra et sinistra